Welcome to our dedicated page for Viatris news (Ticker: VTRS), a resource for investors and traders seeking the latest updates and insights on Viatris stock.
Viatris Inc. reports developments for a global healthcare company with a portfolio spanning generics, established brands and innovative medicines. News commonly covers quarterly results, guidance, cash deployment, dividends, capital allocation and management changes, alongside product launches and pipeline updates across major therapeutic areas.
Company updates also include scientific presentations and regulatory actions tied to specific medicines and candidates, including Effexor in Japan, ophthalmology programs such as phentolamine ophthalmic solution and RYZUMVI, and an investigational low-dose estrogen combined hormonal contraceptive weekly patch. Viatris was formed through the combination of Mylan and Pfizer's Upjohn business and operates with global centers in the U.S., China and India.
Viatris (Nasdaq: VTRS) received U.S. FDA approval for Gwyn Lo™, a once-weekly combined hormonal contraceptive patch (norelgestromin 220 mcg/day and ethinyl estradiol 20 mcg/day) for pregnancy prevention in women of childbearing potential with BMI < 30 kg/m² who are appropriate CHC candidates.
The 505(b)(2) approval is supported by the Phase 3 Luminous Study, where the Pearl Index in women 18–35 years was 4.14 (95% CI: 2.77–5.95). Patch adhesion was strong, with only 1.3% of 39,790 patches fully detaching over one year. Common adverse reactions (≥2%) included application site irritation (4.8%), erythema (3.7%), pruritus (3.7%), intercycle bleeding (3.9%), heavy withdrawal bleeding (2.0%) and nausea (2.0%). Cycle control improved over time, with unscheduled bleeding/spotting declining from 34.5% (3.2 days) in Cycle 1 to 20.0% (2.4 days) by Cycle 13. Viatris expects Gwyn Lo to be commercially available in the U.S. later in 2026.
Viatris (Nasdaq: VTRS) announced it will report second-quarter 2026 financial results on Thursday, August 6, 2026. Company executives will host a conference call and live webcast at 8:30 a.m. ET the same day, accessible via investor.viatris.com and dedicated phone lines.
Viatris (Nasdaq: VTRS) reported positive top-line Phase 3 results for VR-205 (targeted-release budesonide, Nefecon) in Japanese adults with primary IgA nephropathy.
The trial met its primary endpoint with a 33.75% UPCR reduction at 9 months, showed multiple renal function improvements, and was generally well tolerated. A Japanese New Drug Application is targeted by end of 2026.
Viatris (Nasdaq: VTRS) announced that the U.S. FDA has accepted its New Drug Application for MR-107A-02 fast-acting meloxicam, a non-opioid treatment for moderate-to-severe acute pain. The FDA set a PDUFA goal date of Dec. 27, 2026.
The NDA is backed by two Phase 3 randomized, double-blind, placebo- and active-controlled trials in herniorrhaphy and bunionectomy patients. Fast-acting meloxicam met primary and secondary endpoints, reduced opioid use, and showed a safety profile consistent with its mechanism of action.
Viatris (Nasdaq: VTRS) will present at the Bank of America Securities 2026 Healthcare Conference on Tuesday, May 12, 2026 at 8:00 a.m. PT / 11:00 a.m. ET. A live webcast will be available at investor.viatris.com, with an archived version accessible there for a limited time.
Viatris (Nasdaq: VTRS) reported Q1 2026 total revenues of $3.52B, up 8% reported and 3% operationally; U.S. GAAP net earnings were $176M and Adjusted EBITDA was $1.05B. The company reaffirmed 2026 guidance, including $14.45–$14.95B revenue and $4.15–$4.45B adjusted EBITDA, and expects >$2.5B cash available for deployment in 2026.
Key regional strength was Greater China; operational headwinds included ARV supply constraints in Emerging Markets. Cash from operations and free cash flow were lower versus Q1 2025.
Viatris (Nasdaq: VTRS) announced a quarterly dividend of $0.12 per share, declared May 4, 2026. The dividend is payable on June 17, 2026 to shareholders of record at the close of business on May 22, 2026.
Viatris (Nasdaq: VTRS) announced that Chief Financial Officer Theodora "Doretta" Mistras will depart for a new professional opportunity; she will remain through May 22, 2026.
Paul Campbell, Chief Accounting Officer and Corporate Controller, is named interim CFO effective May 8, 2026 while a permanent successor search is conducted. Viatris will report Q1 2026 results on May 7, 2026 and host an 8:30 a.m. ET conference call.
Viatris (Nasdaq: VTRS) announced six abstracts on its investigational low-dose estrogen combined hormonal contraceptive (MR-100A-01) will be presented at the ACOG 2026 Annual Clinical & Scientific Meeting in Washington, D.C., May 1–3, 2026. Presentations include positive Phase 3 efficacy and safety results, adhesion and pharmacokinetic data, and cycle control findings. Sessions and times for six electronic poster presentations and an educational symposium supported by Viatris are listed; Viatris will be at booth #223.
Viatris (Nasdaq: VTRS) will report first quarter 2026 financial results on Thursday, May 7, 2026. Company executives will host a live webcast at 8:30 a.m. ET the same day to discuss results.
Investors can access the live webcast at investor.viatris.com, call 844.308.3344 (domestic) or 412.317.1896 (international). A replay will be available on the company website after the call.